Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
7.34
-0.03 (-0.41%)
At close: Dec 20, 2024, 4:00 PM
7.39
+0.05 (0.68%)
After-hours: Dec 20, 2024, 6:39 PM EST
Vir Biotechnology Employees
Vir Biotechnology had 587 employees as of December 31, 2023. The number of employees increased by 11 or 1.91% compared to the previous year.
Employees
587
Change (1Y)
11
Growth (1Y)
1.91%
Revenue / Employee
$133,932
Profits / Employee
-$908,593
Market Cap
1.01B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 587 | 11 | 1.91% |
Dec 31, 2022 | 576 | 132 | 29.73% |
Dec 31, 2021 | 444 | 117 | 35.78% |
Dec 31, 2020 | 327 | 98 | 42.79% |
Dec 31, 2019 | 229 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
Owens & Minor | 22,200 |
Tilray Brands | 2,650 |
Bicycle Therapeutics | 284 |
Rocket Pharmaceuticals | 268 |
Collegium Pharmaceutical | 197 |
Avadel Pharmaceuticals | 154 |
Pharvaris | 82 |
VIR News
- 3 days ago - Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 8 days ago - Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January - Seeking Alpha
- 9 days ago - Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - Business Wire
- 25 days ago - Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs - Business Wire
- 26 days ago - Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 4 weeks ago - Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Business Wire
- 4 weeks ago - Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - Business Wire
- 5 weeks ago - Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire